Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy

Cleo E. Rolle, Roberto Carrio, Thomas Malek

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Adoptive T-cell therapy with CD8+ CTLs is often characterized by poor persistence of the transferred T cells and limited effector responses. Improved persistence and therapeutic efficacy have been noted when antigen-activated CD8+ T cells express properties of memory cells. The current study was undertaken to more precisely characterize the development of memory-like CD8+ T cells from short-term CTLs in vitro and upon transfer in vivo, including their antitumor activity. Ovalbumin (OVA)-specific OT-I CTLs acquired phenotypic and functional properties of memory cells 2 to 3 days later either by lowering the concentration of antigen to a level that does not support primary responses and providing a survival signal through transgenic Bcl-2 in vitro or simply by transferring early day 3 CTLs to antigen-free lymphoid-replete mice. In lymphoid-replete mice, established OVA-expressing E.G7 tumor was rejected by short-term CTLs that simultaneously acquired memory-like properties in secondary lymphoid tissues, where tumor antigen level remained low. Collectively, these data indicate that CTLs readily converted to memory-like cells upon lowering antigen to a concentration that selectively supports memory responses and suggest that such conversion predicts successful adoptive immunotherapy.

Original languageEnglish
Pages (from-to)2984-2992
Number of pages9
JournalCancer Research
Volume68
Issue number8
DOIs
StatePublished - Apr 15 2008

Fingerprint

Immunotherapy
T-Lymphocytes
Ovalbumin
Antigens
CD8 Antigens
Adoptive Immunotherapy
Lymphoid Tissue
Neoplasm Antigens
Cell- and Tissue-Based Therapy
Neoplasms
In Vitro Techniques
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy. / Rolle, Cleo E.; Carrio, Roberto; Malek, Thomas.

In: Cancer Research, Vol. 68, No. 8, 15.04.2008, p. 2984-2992.

Research output: Contribution to journalArticle

@article{2dbe9a992dbd4d4eabedc4de804025a0,
title = "Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy",
abstract = "Adoptive T-cell therapy with CD8+ CTLs is often characterized by poor persistence of the transferred T cells and limited effector responses. Improved persistence and therapeutic efficacy have been noted when antigen-activated CD8+ T cells express properties of memory cells. The current study was undertaken to more precisely characterize the development of memory-like CD8+ T cells from short-term CTLs in vitro and upon transfer in vivo, including their antitumor activity. Ovalbumin (OVA)-specific OT-I CTLs acquired phenotypic and functional properties of memory cells 2 to 3 days later either by lowering the concentration of antigen to a level that does not support primary responses and providing a survival signal through transgenic Bcl-2 in vitro or simply by transferring early day 3 CTLs to antigen-free lymphoid-replete mice. In lymphoid-replete mice, established OVA-expressing E.G7 tumor was rejected by short-term CTLs that simultaneously acquired memory-like properties in secondary lymphoid tissues, where tumor antigen level remained low. Collectively, these data indicate that CTLs readily converted to memory-like cells upon lowering antigen to a concentration that selectively supports memory responses and suggest that such conversion predicts successful adoptive immunotherapy.",
author = "Rolle, {Cleo E.} and Roberto Carrio and Thomas Malek",
year = "2008",
month = "4",
day = "15",
doi = "10.1158/0008-5472.CAN-07-3040",
language = "English",
volume = "68",
pages = "2984--2992",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Modeling the CD8+ T effector to memory transition in adoptive T-cell antitumor immunotherapy

AU - Rolle, Cleo E.

AU - Carrio, Roberto

AU - Malek, Thomas

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Adoptive T-cell therapy with CD8+ CTLs is often characterized by poor persistence of the transferred T cells and limited effector responses. Improved persistence and therapeutic efficacy have been noted when antigen-activated CD8+ T cells express properties of memory cells. The current study was undertaken to more precisely characterize the development of memory-like CD8+ T cells from short-term CTLs in vitro and upon transfer in vivo, including their antitumor activity. Ovalbumin (OVA)-specific OT-I CTLs acquired phenotypic and functional properties of memory cells 2 to 3 days later either by lowering the concentration of antigen to a level that does not support primary responses and providing a survival signal through transgenic Bcl-2 in vitro or simply by transferring early day 3 CTLs to antigen-free lymphoid-replete mice. In lymphoid-replete mice, established OVA-expressing E.G7 tumor was rejected by short-term CTLs that simultaneously acquired memory-like properties in secondary lymphoid tissues, where tumor antigen level remained low. Collectively, these data indicate that CTLs readily converted to memory-like cells upon lowering antigen to a concentration that selectively supports memory responses and suggest that such conversion predicts successful adoptive immunotherapy.

AB - Adoptive T-cell therapy with CD8+ CTLs is often characterized by poor persistence of the transferred T cells and limited effector responses. Improved persistence and therapeutic efficacy have been noted when antigen-activated CD8+ T cells express properties of memory cells. The current study was undertaken to more precisely characterize the development of memory-like CD8+ T cells from short-term CTLs in vitro and upon transfer in vivo, including their antitumor activity. Ovalbumin (OVA)-specific OT-I CTLs acquired phenotypic and functional properties of memory cells 2 to 3 days later either by lowering the concentration of antigen to a level that does not support primary responses and providing a survival signal through transgenic Bcl-2 in vitro or simply by transferring early day 3 CTLs to antigen-free lymphoid-replete mice. In lymphoid-replete mice, established OVA-expressing E.G7 tumor was rejected by short-term CTLs that simultaneously acquired memory-like properties in secondary lymphoid tissues, where tumor antigen level remained low. Collectively, these data indicate that CTLs readily converted to memory-like cells upon lowering antigen to a concentration that selectively supports memory responses and suggest that such conversion predicts successful adoptive immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=42349085267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42349085267&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-3040

DO - 10.1158/0008-5472.CAN-07-3040

M3 - Article

VL - 68

SP - 2984

EP - 2992

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 8

ER -